Literature DB >> 11460142

New-age drug meets resistance.

F McCormick.   

Abstract

Mesh：

Substances：

Year:  2001        PMID： 11460142     DOI： 10.1038/35085665

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  6 in total

1.  Origin of multidrug resistance in cells with and without multidrug resistance genes: chromosome reassortments catalyzed by aneuploidy.

Authors:  P Duesberg; R Stindl; R Hehlmann
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

2.  Can engineered bacteria help control cancer?

Authors:  R K Jain; N S Forbes
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

Review 3.  Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism.

Authors:  Bertrand Rochat
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

4.  Drug resistance in cancer: principles of emergence and prevention.

Authors:  Natalia L Komarova; Dominik Wodarz
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-24       Impact factor: 11.205

5.  The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib.

Authors:  Roos L Oostendorp; Tessa Buckle; Jos H Beijnen; Olaf van Tellingen; Jan H M Schellens
Journal:  Invest New Drugs       Date:  2008-05-01       Impact factor: 3.850

Review 6.  Karyotype Aberrations in Action: The Evolution of Cancer Genomes and the Tumor Microenvironment.

Authors:  Nicolaas C Baudoin; Mathew Bloomfield
Journal:  Genes (Basel)       Date:  2021-04-12       Impact factor: 4.096
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.